Chemed Corp (NYSE:CHE) President and CEO Kevin J. McNamara has sold a portion of his holdings in the company, according to a recent filing with the Securities and Exchange Commission. The transactions, which occurred on August 5, 2024, involved the sale of 2,000 shares at a weighted average price of $569.63, totaling over $1.1 million. The sales were conducted in multiple transactions ranging from $565.63 to $579.09 per share.
In addition to the sales, McNamara also engaged in transactions that indicated his continued investment in the company. He acquired 5,000 shares through the exercise of options at a price of $445.35 per share, amounting to a total of $2,226,750. This transaction reflects his vested interest in the company and aligns with the executive's compensation structure.
Furthermore, the filing revealed that McNamara also exercised options as part of a tax obligation related to the stock option exercise, which resulted in the disposition of 4,314 shares at $586.14 each, for a total of $2,528,607.
Following these transactions, McNamara's direct ownership in Chemed Corp stands at 105,735 shares of capital stock. It's important to note that the executive's actions are a routine part of managing personal investment portfolios and are often scheduled in advance.
Investors and market watchers typically monitor insider transactions like these for insights into executive sentiment regarding their company's stock. However, such sales and purchases can be influenced by a variety of factors and do not necessarily indicate a change in company performance or outlook.
Chemed Corp, known for its healthcare services, including its Roto-Rooter brand, remains a significant player in the industry. As with any insider transactions, shareholders consider the context of the broader market and the company's current position when assessing the potential impact on their investments.
In other recent news, Chemed Corporation has announced an increase in its quarterly cash dividend by 25%, resulting in a payout of 50 cents per share. This marks a continued trend of consistent shareholder returns, with Chemed having issued dividends for 213 consecutive quarters. In other developments, RBC Capital has revised its price target for Chemed shares to $697, while maintaining an Outperform rating. The adjustment follows a review of the company's Q1 2024 performance, highlighting strong results from the VITAS Healthcare unit and challenges faced by the Roto-Rooter business. Furthermore, Chemed shareholders recently elected a slate of 10 directors and ratified the appointment of PricewaterhouseCoopers LLP as the company's independent accountants for 2024. These are the latest developments for Chemed Corporation.
InvestingPro Insights
Recent insider transactions at Chemed Corp (NYSE:CHE) have drawn attention to the company's financial metrics and performance. According to InvestingPro data, Chemed Corp has a market capitalization of $8.74 billion and is trading at a P/E ratio of 29.25, which adjusts to 28.38 when considering the last twelve months as of Q2 2024. This valuation comes with a PEG ratio of 0.9, indicating a potentially fair price relative to the company's earnings growth.
The company's revenue has grown by 6.79% over the last twelve months leading up to Q2 2024, with a quarterly growth rate of 7.6%. This consistent growth is complemented by a robust gross profit margin of 35.96%, showcasing the company's ability to maintain profitability.
Among the InvestingPro Tips, it's notable that Chemed Corp has raised its dividend for 15 consecutive years and has maintained dividend payments for an impressive 54 consecutive years. This consistency in rewarding shareholders may be of particular interest to investors looking for stable income-generating stocks. Additionally, the company is trading at a high Price / Book multiple of 7.22, which could suggest a premium valuation compared to its book value.
For those interested in further insights, InvestingPro offers additional tips on Chemed Corp, including its low price volatility and the company's ability to cover interest payments with its cash flows. There are a total of 10 InvestingPro Tips available for Chemed Corp, which can be accessed for more in-depth analysis and investment considerations at: https://www.investing.com/pro/CHE
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.